Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Treosulfan/Melphalan Consolidation in High-Risk Ewing Sarcoma
2024-518912-37-01Phase 2Authorised
- Sponsor
- Fondazione Santobono Pausilipon
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan and melphalan in Ewing sarcoma and Ewing-like sarcoma, sponsored by Fondazione Santobono Pausilipon. Primary endpoints: Safety (Adverse Events and Serious Adverse Events) and Event-Free Survival at 36 months. Planned start Dec 2024; status: authorised.
02
Drugs
treosulfanmelphalan
03
Conditions
Ewing sarcomaEwing-like sarcoma
Beyond the preview
Go deeper on 2024-518912-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518912-37-01.